Ocrelizumab Side Effects
Summary
Commonly reported side effects of ocrelizumab include: lower respiratory tract infection, upper respiratory tract infection, cough, and infusion related reaction. Continue reading for a comprehensive list of adverse effects.
Applies to ocrelizumab: parenteral concentrate for iv infusion.
Side effects include:
Relapsing forms of MS (≥10%): upper respiratory tract infection and infusion reaction.
PPMS (≥10%): upper respiratory tract infection, infusion reaction, skin infection, and lower respiratory tract infection.
For Healthcare Professionals
Applies to ocrelizumab: intravenous solution.
Respiratory
Very common (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)
Common (1% to 10%): Bronchitis, cough[Ref]
Psychiatric
Common (1% to 10%): Depression[Ref]
Oncologic
Uncommon (0.1% to 1%): Breast cancer[Ref]
Musculoskeletal
Common (1% to 10%): Back pain, pain in extremity[Ref]
Local
Very common (10% or more): Infusion reactions (40%)[Ref]
Immunologic
Common (1% to 10%): Herpes virus associated infections
Frequency not reported: Immunogenicity[Ref]
Hematologic
Very common (10% or more): Neutrophil levels decreased (13%)[Ref]
Dermatologic
Very common (10% or more): Skin infections (14%)[Ref]
Ocular
Common (1% to 10%): Conjunctivitis[Ref]
Metabolic
Common (1% to 10%): Peripheral edema[Ref]
Frequently asked questions
- How much does an Ocrevus infusion cost?
- How long does it take Ocrevus to work?
- Is Ocrevus a form of chemotherapy?
- How long does an Ocrevus infusion take?
- How does Ocrevus work for MS?
- What are the new drugs used for multiple sclerosis (MS)?
- Ocrevus vs Aubagio: How do they compare for MS?
More about ocrelizumab
- Check interactions
- Compare alternatives
- Reviews (167)
- Dosage information
- During pregnancy
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
References
1. Product Information. Ocrevus (ocrelizumab). Genentech. 2017.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
